Second allogeneic transplants for multiple myeloma: a report from the EBMT Chronic Malignancies Working Party
The EBMT Chronic Malignancies Working Party performed a retrospective analysis of 215 patients who underwent a second allo-HCT for myeloma between 1994 and 2017, 159 for relapse and 56 for graft failure. In the relapse group, overall survival (OS) was 38% (30–46%) at 2 years and 25% (17–32%) at 5 ye...
Gespeichert in:
| Veröffentlicht in: | Bone marrow transplantation (Basingstoke) 2021-10, Vol.56 (10), p.2367-2381 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2381 |
|---|---|
| container_issue | 10 |
| container_start_page | 2367 |
| container_title | Bone marrow transplantation (Basingstoke) |
| container_volume | 56 |
| creator | Hayden, Patrick J. Eikema, Dirk-Jan de Wreede, Liesbeth C. Koster, Linda Kröger, Nicolaus Einsele, Hermann Minnema, Monique Dominietto, Alida Potter, Michael Passweg, Jacob Bermúdez, Arancha Nguyen-quoc, Stephanie Platzbecker, Uwe Tischer, Johanna Ciceri, Fabio Veelken, Joan Hendrik Ljungman, Per Schaap, Nicolaas Forcade, Edouard Carella, Angelo Michele Gandemer, Virginie Arcese, William Bloor, Adrian Olivieri, Attilio Vincent, Laure Beksac, Meral Schönland, Stefan Yakoub-Agha, Ibrahim |
| description | The EBMT Chronic Malignancies Working Party performed a retrospective analysis of 215 patients who underwent a second allo-HCT for myeloma between 1994 and 2017, 159 for relapse and 56 for graft failure. In the relapse group, overall survival (OS) was 38% (30–46%) at 2 years and 25% (17–32%) at 5 years. Patients who had a HLA-identical sibling (HLAid-Sib) donor for their first and second transplants had superior OS (5 year OS: HLAid-Sib/HLAid-Sib: 35% (24–46%); Others 9% (0–17%),
p
|
| doi_str_mv | 10.1038/s41409-021-01286-x |
| format | Article |
| fullrecord | <record><control><sourceid>gale_swepu</sourceid><recordid>TN_cdi_swepub_primary_oai_swepub_ki_se_462090</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A677555847</galeid><sourcerecordid>A677555847</sourcerecordid><originalsourceid>FETCH-LOGICAL-c694t-b2e0ecc53a8d54aa68a8c8c11625f053101a8789cf7358cffb1721f689fbf3f3</originalsourceid><addsrcrecordid>eNp9kl9rUzEYxg-iuDr9Al5IQBC9ODP_T84uhFqmEzoULHgZ0jRps-UkNTmd67c3td26DpVcJLz5PU-SN09VvUTwBEEi3meKKGxriFENERa8vnlUDRBteM0IZ4-rAcRc1ITw9qh6lvMlhIhSyJ5WR4S0DScCD6ruu9ExzIDyPs5NME6DPqmQl16FPgMbE-hWvndLb0C3Nj526hQokMwyph7YFDvQLww4-3gxAaNFiqEYXCjv5kEF7UwGP2K6cmEOvqnUr59XT6zy2bzYzcfV5NPZZHRej79-_jIajmvNW9rXU2yg0ZoRJWaMKsWFElpohDhmFjKCIFKiEa22DWFCWztFDUaWi9ZOLbHkuKq3tvmXWa6mcplcp9JaRuXkrnRVVkZSjmELC9_-k1-mONuLboWIctpywXjRfthqC9CZmTah9M8fWhzsBLeQ83gtBRWcN5vD320NFg9k58Ox3NQgpVhQIq5RYd_uDkvx58rkXnYua-PLZ5m4yhIzzBERkLcFff0AvYyrFErXC9UIzCnibE_NlTfSBRvLHfXGVA550zDGBG0KdfIXqoyZ6VyJj7Gu1A8Eb-4JFkb5fpGjX_UuhnwI4i2oU8w5GXvXAQTlJuRyG3JZQi7_hFzeFNGr-y2_k9ymugBk959lK8xN2r_9P7a_AfelCEs</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2578264165</pqid></control><display><type>article</type><title>Second allogeneic transplants for multiple myeloma: a report from the EBMT Chronic Malignancies Working Party</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><source>SWEPUB Freely available online</source><source>EZB Electronic Journals Library</source><creator>Hayden, Patrick J. ; Eikema, Dirk-Jan ; de Wreede, Liesbeth C. ; Koster, Linda ; Kröger, Nicolaus ; Einsele, Hermann ; Minnema, Monique ; Dominietto, Alida ; Potter, Michael ; Passweg, Jacob ; Bermúdez, Arancha ; Nguyen-quoc, Stephanie ; Platzbecker, Uwe ; Tischer, Johanna ; Ciceri, Fabio ; Veelken, Joan Hendrik ; Ljungman, Per ; Schaap, Nicolaas ; Forcade, Edouard ; Carella, Angelo Michele ; Gandemer, Virginie ; Arcese, William ; Bloor, Adrian ; Olivieri, Attilio ; Vincent, Laure ; Beksac, Meral ; Schönland, Stefan ; Yakoub-Agha, Ibrahim</creator><creatorcontrib>Hayden, Patrick J. ; Eikema, Dirk-Jan ; de Wreede, Liesbeth C. ; Koster, Linda ; Kröger, Nicolaus ; Einsele, Hermann ; Minnema, Monique ; Dominietto, Alida ; Potter, Michael ; Passweg, Jacob ; Bermúdez, Arancha ; Nguyen-quoc, Stephanie ; Platzbecker, Uwe ; Tischer, Johanna ; Ciceri, Fabio ; Veelken, Joan Hendrik ; Ljungman, Per ; Schaap, Nicolaas ; Forcade, Edouard ; Carella, Angelo Michele ; Gandemer, Virginie ; Arcese, William ; Bloor, Adrian ; Olivieri, Attilio ; Vincent, Laure ; Beksac, Meral ; Schönland, Stefan ; Yakoub-Agha, Ibrahim</creatorcontrib><description>The EBMT Chronic Malignancies Working Party performed a retrospective analysis of 215 patients who underwent a second allo-HCT for myeloma between 1994 and 2017, 159 for relapse and 56 for graft failure. In the relapse group, overall survival (OS) was 38% (30–46%) at 2 years and 25% (17–32%) at 5 years. Patients who had a HLA-identical sibling (HLAid-Sib) donor for their first and second transplants had superior OS (5 year OS: HLAid-Sib/HLAid-Sib: 35% (24–46%); Others 9% (0–17%),
p
< 0.001). There was a significantly higher incidence of acute grade II-IV GvHD in those patients who had also developed GvHD following their initial HLA-identical sibling allo-HCT (HLAid-Sib/HLAid-Sib: 50% (33–67%); Other 22% (8–36%),
p
= 0.03). More as opposed to fewer than 2 years between transplants was associated with superior 5-yr OS (31% (21–40%) vs. 10% (1–20%),
P
= 0.005). On multivariate analysis, consecutive HLA-identical sibling donor transplants conferred a significant OS advantage (0.4 (0.24–0.67),
p
< 0.001). In the graft failure group, OS was 41% at 2 years. In summary, a second allo-HCT using a HLA-identical sibling donor, if available, provides the best transplant outcomes for relapsed myeloma in this setting.</description><identifier>ISSN: 0268-3369</identifier><identifier>ISSN: 1476-5365</identifier><identifier>EISSN: 1476-5365</identifier><identifier>DOI: 10.1038/s41409-021-01286-x</identifier><identifier>PMID: 33976382</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>692/700/565/2319 ; 692/700/565/251 ; Allografts ; Cancer ; Care and treatment ; Cell Biology ; Graft rejection ; Graft vs Host Disease ; Graft-versus-host reaction ; Grafts ; Hematology ; Hematopoietic Stem Cell Transplantation ; Hematopoietic stem cells ; Histocompatibility antigen HLA ; Humans ; Internal Medicine ; Life Sciences ; Medicin och hälsovetenskap ; Medicine ; Medicine & Public Health ; Multiple myeloma ; Multiple Myeloma - therapy ; Multivariate analysis ; Neoplasm Recurrence, Local ; Patient outcomes ; Public Health ; Relapse ; Retrospective Studies ; Stem cell transplantation ; Stem Cells ; Transplantation ; Transplantation Conditioning ; Transplants ; Transplants & implants</subject><ispartof>Bone marrow transplantation (Basingstoke), 2021-10, Vol.56 (10), p.2367-2381</ispartof><rights>The Author(s) 2021</rights><rights>2021. The Author(s).</rights><rights>COPYRIGHT 2021 Nature Publishing Group</rights><rights>The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Attribution</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c694t-b2e0ecc53a8d54aa68a8c8c11625f053101a8789cf7358cffb1721f689fbf3f3</citedby><cites>FETCH-LOGICAL-c694t-b2e0ecc53a8d54aa68a8c8c11625f053101a8789cf7358cffb1721f689fbf3f3</cites><orcidid>0000-0002-8281-3245 ; 0000-0003-4550-220X ; 0000-0003-1374-4503 ; 0000-0002-8873-2868 ; 0000-0002-9108-3125 ; 0000-0001-5697-366X ; 0000-0002-4853-5579 ; 0000-0003-4524-8782 ; 0000-0001-5904-1286</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,552,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33976382$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.univ-lille.fr/hal-04428438$$DView record in HAL$$Hfree_for_read</backlink><backlink>$$Uhttp://kipublications.ki.se/Default.aspx?queryparsed=id:146496856$$DView record from Swedish Publication Index$$Hfree_for_read</backlink></links><search><creatorcontrib>Hayden, Patrick J.</creatorcontrib><creatorcontrib>Eikema, Dirk-Jan</creatorcontrib><creatorcontrib>de Wreede, Liesbeth C.</creatorcontrib><creatorcontrib>Koster, Linda</creatorcontrib><creatorcontrib>Kröger, Nicolaus</creatorcontrib><creatorcontrib>Einsele, Hermann</creatorcontrib><creatorcontrib>Minnema, Monique</creatorcontrib><creatorcontrib>Dominietto, Alida</creatorcontrib><creatorcontrib>Potter, Michael</creatorcontrib><creatorcontrib>Passweg, Jacob</creatorcontrib><creatorcontrib>Bermúdez, Arancha</creatorcontrib><creatorcontrib>Nguyen-quoc, Stephanie</creatorcontrib><creatorcontrib>Platzbecker, Uwe</creatorcontrib><creatorcontrib>Tischer, Johanna</creatorcontrib><creatorcontrib>Ciceri, Fabio</creatorcontrib><creatorcontrib>Veelken, Joan Hendrik</creatorcontrib><creatorcontrib>Ljungman, Per</creatorcontrib><creatorcontrib>Schaap, Nicolaas</creatorcontrib><creatorcontrib>Forcade, Edouard</creatorcontrib><creatorcontrib>Carella, Angelo Michele</creatorcontrib><creatorcontrib>Gandemer, Virginie</creatorcontrib><creatorcontrib>Arcese, William</creatorcontrib><creatorcontrib>Bloor, Adrian</creatorcontrib><creatorcontrib>Olivieri, Attilio</creatorcontrib><creatorcontrib>Vincent, Laure</creatorcontrib><creatorcontrib>Beksac, Meral</creatorcontrib><creatorcontrib>Schönland, Stefan</creatorcontrib><creatorcontrib>Yakoub-Agha, Ibrahim</creatorcontrib><title>Second allogeneic transplants for multiple myeloma: a report from the EBMT Chronic Malignancies Working Party</title><title>Bone marrow transplantation (Basingstoke)</title><addtitle>Bone Marrow Transplant</addtitle><addtitle>Bone Marrow Transplant</addtitle><description>The EBMT Chronic Malignancies Working Party performed a retrospective analysis of 215 patients who underwent a second allo-HCT for myeloma between 1994 and 2017, 159 for relapse and 56 for graft failure. In the relapse group, overall survival (OS) was 38% (30–46%) at 2 years and 25% (17–32%) at 5 years. Patients who had a HLA-identical sibling (HLAid-Sib) donor for their first and second transplants had superior OS (5 year OS: HLAid-Sib/HLAid-Sib: 35% (24–46%); Others 9% (0–17%),
p
< 0.001). There was a significantly higher incidence of acute grade II-IV GvHD in those patients who had also developed GvHD following their initial HLA-identical sibling allo-HCT (HLAid-Sib/HLAid-Sib: 50% (33–67%); Other 22% (8–36%),
p
= 0.03). More as opposed to fewer than 2 years between transplants was associated with superior 5-yr OS (31% (21–40%) vs. 10% (1–20%),
P
= 0.005). On multivariate analysis, consecutive HLA-identical sibling donor transplants conferred a significant OS advantage (0.4 (0.24–0.67),
p
< 0.001). In the graft failure group, OS was 41% at 2 years. In summary, a second allo-HCT using a HLA-identical sibling donor, if available, provides the best transplant outcomes for relapsed myeloma in this setting.</description><subject>692/700/565/2319</subject><subject>692/700/565/251</subject><subject>Allografts</subject><subject>Cancer</subject><subject>Care and treatment</subject><subject>Cell Biology</subject><subject>Graft rejection</subject><subject>Graft vs Host Disease</subject><subject>Graft-versus-host reaction</subject><subject>Grafts</subject><subject>Hematology</subject><subject>Hematopoietic Stem Cell Transplantation</subject><subject>Hematopoietic stem cells</subject><subject>Histocompatibility antigen HLA</subject><subject>Humans</subject><subject>Internal Medicine</subject><subject>Life Sciences</subject><subject>Medicin och hälsovetenskap</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Multiple myeloma</subject><subject>Multiple Myeloma - therapy</subject><subject>Multivariate analysis</subject><subject>Neoplasm Recurrence, Local</subject><subject>Patient outcomes</subject><subject>Public Health</subject><subject>Relapse</subject><subject>Retrospective Studies</subject><subject>Stem cell transplantation</subject><subject>Stem Cells</subject><subject>Transplantation</subject><subject>Transplantation Conditioning</subject><subject>Transplants</subject><subject>Transplants & implants</subject><issn>0268-3369</issn><issn>1476-5365</issn><issn>1476-5365</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>D8T</sourceid><recordid>eNp9kl9rUzEYxg-iuDr9Al5IQBC9ODP_T84uhFqmEzoULHgZ0jRps-UkNTmd67c3td26DpVcJLz5PU-SN09VvUTwBEEi3meKKGxriFENERa8vnlUDRBteM0IZ4-rAcRc1ITw9qh6lvMlhIhSyJ5WR4S0DScCD6ruu9ExzIDyPs5NME6DPqmQl16FPgMbE-hWvndLb0C3Nj526hQokMwyph7YFDvQLww4-3gxAaNFiqEYXCjv5kEF7UwGP2K6cmEOvqnUr59XT6zy2bzYzcfV5NPZZHRej79-_jIajmvNW9rXU2yg0ZoRJWaMKsWFElpohDhmFjKCIFKiEa22DWFCWztFDUaWi9ZOLbHkuKq3tvmXWa6mcplcp9JaRuXkrnRVVkZSjmELC9_-k1-mONuLboWIctpywXjRfthqC9CZmTah9M8fWhzsBLeQ83gtBRWcN5vD320NFg9k58Ox3NQgpVhQIq5RYd_uDkvx58rkXnYua-PLZ5m4yhIzzBERkLcFff0AvYyrFErXC9UIzCnibE_NlTfSBRvLHfXGVA550zDGBG0KdfIXqoyZ6VyJj7Gu1A8Eb-4JFkb5fpGjX_UuhnwI4i2oU8w5GXvXAQTlJuRyG3JZQi7_hFzeFNGr-y2_k9ymugBk959lK8xN2r_9P7a_AfelCEs</recordid><startdate>20211001</startdate><enddate>20211001</enddate><creator>Hayden, Patrick J.</creator><creator>Eikema, Dirk-Jan</creator><creator>de Wreede, Liesbeth C.</creator><creator>Koster, Linda</creator><creator>Kröger, Nicolaus</creator><creator>Einsele, Hermann</creator><creator>Minnema, Monique</creator><creator>Dominietto, Alida</creator><creator>Potter, Michael</creator><creator>Passweg, Jacob</creator><creator>Bermúdez, Arancha</creator><creator>Nguyen-quoc, Stephanie</creator><creator>Platzbecker, Uwe</creator><creator>Tischer, Johanna</creator><creator>Ciceri, Fabio</creator><creator>Veelken, Joan Hendrik</creator><creator>Ljungman, Per</creator><creator>Schaap, Nicolaas</creator><creator>Forcade, Edouard</creator><creator>Carella, Angelo Michele</creator><creator>Gandemer, Virginie</creator><creator>Arcese, William</creator><creator>Bloor, Adrian</creator><creator>Olivieri, Attilio</creator><creator>Vincent, Laure</creator><creator>Beksac, Meral</creator><creator>Schönland, Stefan</creator><creator>Yakoub-Agha, Ibrahim</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QO</scope><scope>7QP</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>1XC</scope><scope>VOOES</scope><scope>5PM</scope><scope>ADTPV</scope><scope>AOWAS</scope><scope>D8T</scope><scope>ZZAVC</scope><orcidid>https://orcid.org/0000-0002-8281-3245</orcidid><orcidid>https://orcid.org/0000-0003-4550-220X</orcidid><orcidid>https://orcid.org/0000-0003-1374-4503</orcidid><orcidid>https://orcid.org/0000-0002-8873-2868</orcidid><orcidid>https://orcid.org/0000-0002-9108-3125</orcidid><orcidid>https://orcid.org/0000-0001-5697-366X</orcidid><orcidid>https://orcid.org/0000-0002-4853-5579</orcidid><orcidid>https://orcid.org/0000-0003-4524-8782</orcidid><orcidid>https://orcid.org/0000-0001-5904-1286</orcidid></search><sort><creationdate>20211001</creationdate><title>Second allogeneic transplants for multiple myeloma: a report from the EBMT Chronic Malignancies Working Party</title><author>Hayden, Patrick J. ; Eikema, Dirk-Jan ; de Wreede, Liesbeth C. ; Koster, Linda ; Kröger, Nicolaus ; Einsele, Hermann ; Minnema, Monique ; Dominietto, Alida ; Potter, Michael ; Passweg, Jacob ; Bermúdez, Arancha ; Nguyen-quoc, Stephanie ; Platzbecker, Uwe ; Tischer, Johanna ; Ciceri, Fabio ; Veelken, Joan Hendrik ; Ljungman, Per ; Schaap, Nicolaas ; Forcade, Edouard ; Carella, Angelo Michele ; Gandemer, Virginie ; Arcese, William ; Bloor, Adrian ; Olivieri, Attilio ; Vincent, Laure ; Beksac, Meral ; Schönland, Stefan ; Yakoub-Agha, Ibrahim</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c694t-b2e0ecc53a8d54aa68a8c8c11625f053101a8789cf7358cffb1721f689fbf3f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>692/700/565/2319</topic><topic>692/700/565/251</topic><topic>Allografts</topic><topic>Cancer</topic><topic>Care and treatment</topic><topic>Cell Biology</topic><topic>Graft rejection</topic><topic>Graft vs Host Disease</topic><topic>Graft-versus-host reaction</topic><topic>Grafts</topic><topic>Hematology</topic><topic>Hematopoietic Stem Cell Transplantation</topic><topic>Hematopoietic stem cells</topic><topic>Histocompatibility antigen HLA</topic><topic>Humans</topic><topic>Internal Medicine</topic><topic>Life Sciences</topic><topic>Medicin och hälsovetenskap</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Multiple myeloma</topic><topic>Multiple Myeloma - therapy</topic><topic>Multivariate analysis</topic><topic>Neoplasm Recurrence, Local</topic><topic>Patient outcomes</topic><topic>Public Health</topic><topic>Relapse</topic><topic>Retrospective Studies</topic><topic>Stem cell transplantation</topic><topic>Stem Cells</topic><topic>Transplantation</topic><topic>Transplantation Conditioning</topic><topic>Transplants</topic><topic>Transplants & implants</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hayden, Patrick J.</creatorcontrib><creatorcontrib>Eikema, Dirk-Jan</creatorcontrib><creatorcontrib>de Wreede, Liesbeth C.</creatorcontrib><creatorcontrib>Koster, Linda</creatorcontrib><creatorcontrib>Kröger, Nicolaus</creatorcontrib><creatorcontrib>Einsele, Hermann</creatorcontrib><creatorcontrib>Minnema, Monique</creatorcontrib><creatorcontrib>Dominietto, Alida</creatorcontrib><creatorcontrib>Potter, Michael</creatorcontrib><creatorcontrib>Passweg, Jacob</creatorcontrib><creatorcontrib>Bermúdez, Arancha</creatorcontrib><creatorcontrib>Nguyen-quoc, Stephanie</creatorcontrib><creatorcontrib>Platzbecker, Uwe</creatorcontrib><creatorcontrib>Tischer, Johanna</creatorcontrib><creatorcontrib>Ciceri, Fabio</creatorcontrib><creatorcontrib>Veelken, Joan Hendrik</creatorcontrib><creatorcontrib>Ljungman, Per</creatorcontrib><creatorcontrib>Schaap, Nicolaas</creatorcontrib><creatorcontrib>Forcade, Edouard</creatorcontrib><creatorcontrib>Carella, Angelo Michele</creatorcontrib><creatorcontrib>Gandemer, Virginie</creatorcontrib><creatorcontrib>Arcese, William</creatorcontrib><creatorcontrib>Bloor, Adrian</creatorcontrib><creatorcontrib>Olivieri, Attilio</creatorcontrib><creatorcontrib>Vincent, Laure</creatorcontrib><creatorcontrib>Beksac, Meral</creatorcontrib><creatorcontrib>Schönland, Stefan</creatorcontrib><creatorcontrib>Yakoub-Agha, Ibrahim</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Biotechnology Research Abstracts</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>ProQuest Health and Medical</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>ProQuest Biological Science Journals</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><collection>Hyper Article en Ligne (HAL) (Open Access)</collection><collection>PubMed Central (Full Participant titles)</collection><collection>SwePub</collection><collection>SwePub Articles</collection><collection>SWEPUB Freely available online</collection><collection>SwePub Articles full text</collection><jtitle>Bone marrow transplantation (Basingstoke)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hayden, Patrick J.</au><au>Eikema, Dirk-Jan</au><au>de Wreede, Liesbeth C.</au><au>Koster, Linda</au><au>Kröger, Nicolaus</au><au>Einsele, Hermann</au><au>Minnema, Monique</au><au>Dominietto, Alida</au><au>Potter, Michael</au><au>Passweg, Jacob</au><au>Bermúdez, Arancha</au><au>Nguyen-quoc, Stephanie</au><au>Platzbecker, Uwe</au><au>Tischer, Johanna</au><au>Ciceri, Fabio</au><au>Veelken, Joan Hendrik</au><au>Ljungman, Per</au><au>Schaap, Nicolaas</au><au>Forcade, Edouard</au><au>Carella, Angelo Michele</au><au>Gandemer, Virginie</au><au>Arcese, William</au><au>Bloor, Adrian</au><au>Olivieri, Attilio</au><au>Vincent, Laure</au><au>Beksac, Meral</au><au>Schönland, Stefan</au><au>Yakoub-Agha, Ibrahim</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Second allogeneic transplants for multiple myeloma: a report from the EBMT Chronic Malignancies Working Party</atitle><jtitle>Bone marrow transplantation (Basingstoke)</jtitle><stitle>Bone Marrow Transplant</stitle><addtitle>Bone Marrow Transplant</addtitle><date>2021-10-01</date><risdate>2021</risdate><volume>56</volume><issue>10</issue><spage>2367</spage><epage>2381</epage><pages>2367-2381</pages><issn>0268-3369</issn><issn>1476-5365</issn><eissn>1476-5365</eissn><abstract>The EBMT Chronic Malignancies Working Party performed a retrospective analysis of 215 patients who underwent a second allo-HCT for myeloma between 1994 and 2017, 159 for relapse and 56 for graft failure. In the relapse group, overall survival (OS) was 38% (30–46%) at 2 years and 25% (17–32%) at 5 years. Patients who had a HLA-identical sibling (HLAid-Sib) donor for their first and second transplants had superior OS (5 year OS: HLAid-Sib/HLAid-Sib: 35% (24–46%); Others 9% (0–17%),
p
< 0.001). There was a significantly higher incidence of acute grade II-IV GvHD in those patients who had also developed GvHD following their initial HLA-identical sibling allo-HCT (HLAid-Sib/HLAid-Sib: 50% (33–67%); Other 22% (8–36%),
p
= 0.03). More as opposed to fewer than 2 years between transplants was associated with superior 5-yr OS (31% (21–40%) vs. 10% (1–20%),
P
= 0.005). On multivariate analysis, consecutive HLA-identical sibling donor transplants conferred a significant OS advantage (0.4 (0.24–0.67),
p
< 0.001). In the graft failure group, OS was 41% at 2 years. In summary, a second allo-HCT using a HLA-identical sibling donor, if available, provides the best transplant outcomes for relapsed myeloma in this setting.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>33976382</pmid><doi>10.1038/s41409-021-01286-x</doi><tpages>15</tpages><orcidid>https://orcid.org/0000-0002-8281-3245</orcidid><orcidid>https://orcid.org/0000-0003-4550-220X</orcidid><orcidid>https://orcid.org/0000-0003-1374-4503</orcidid><orcidid>https://orcid.org/0000-0002-8873-2868</orcidid><orcidid>https://orcid.org/0000-0002-9108-3125</orcidid><orcidid>https://orcid.org/0000-0001-5697-366X</orcidid><orcidid>https://orcid.org/0000-0002-4853-5579</orcidid><orcidid>https://orcid.org/0000-0003-4524-8782</orcidid><orcidid>https://orcid.org/0000-0001-5904-1286</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0268-3369 |
| ispartof | Bone marrow transplantation (Basingstoke), 2021-10, Vol.56 (10), p.2367-2381 |
| issn | 0268-3369 1476-5365 1476-5365 |
| language | eng |
| recordid | cdi_swepub_primary_oai_swepub_ki_se_462090 |
| source | MEDLINE; Alma/SFX Local Collection; SWEPUB Freely available online; EZB Electronic Journals Library |
| subjects | 692/700/565/2319 692/700/565/251 Allografts Cancer Care and treatment Cell Biology Graft rejection Graft vs Host Disease Graft-versus-host reaction Grafts Hematology Hematopoietic Stem Cell Transplantation Hematopoietic stem cells Histocompatibility antigen HLA Humans Internal Medicine Life Sciences Medicin och hälsovetenskap Medicine Medicine & Public Health Multiple myeloma Multiple Myeloma - therapy Multivariate analysis Neoplasm Recurrence, Local Patient outcomes Public Health Relapse Retrospective Studies Stem cell transplantation Stem Cells Transplantation Transplantation Conditioning Transplants Transplants & implants |
| title | Second allogeneic transplants for multiple myeloma: a report from the EBMT Chronic Malignancies Working Party |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T08%3A43%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_swepu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Second%20allogeneic%20transplants%20for%20multiple%20myeloma:%20a%20report%20from%20the%20EBMT%20Chronic%20Malignancies%20Working%20Party&rft.jtitle=Bone%20marrow%20transplantation%20(Basingstoke)&rft.au=Hayden,%20Patrick%20J.&rft.date=2021-10-01&rft.volume=56&rft.issue=10&rft.spage=2367&rft.epage=2381&rft.pages=2367-2381&rft.issn=0268-3369&rft.eissn=1476-5365&rft_id=info:doi/10.1038/s41409-021-01286-x&rft_dat=%3Cgale_swepu%3EA677555847%3C/gale_swepu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2578264165&rft_id=info:pmid/33976382&rft_galeid=A677555847&rfr_iscdi=true |